Free Trial

Evogene (EVGN) Stock Price, News & Analysis

$0.68
+0.02 (+2.91%)
(As of 03:12 PM ET)
Today's Range
$0.65
$0.68
50-Day Range
$0.61
$0.82
52-Week Range
$0.45
$1.44
Volume
35,390 shs
Average Volume
140,642 shs
Market Capitalization
$28.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.62

Evogene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
431.9% Upside
$3.62 Price Target
Short Interest
Healthy
0.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.89mentions of Evogene in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.49 out of 5 stars

Medical Sector

660th out of 905 stocks

Agricultural Chemicals Industry

8th out of 9 stocks

EVGN stock logo

About Evogene Stock (NASDAQ:EVGN)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

EVGN Stock Price History

EVGN Stock News Headlines

Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com
Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com
Here's what Wall Street expects from Evogene's earnings report
Evogene Earnings Preview
See More Headlines
Receive EVGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
6/12/2024
Next Earnings (Estimated)
8/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Agricultural chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:EVGN
Employees
142
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.62
High Stock Price Target
$6.00
Low Stock Price Target
$1.85
Potential Upside/Downside
+431.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-23,880,000.00
Net Margins
-233.66%
Pretax Margin
-248.19%

Debt

Sales & Book Value

Annual Sales
$5.64 million
Book Value
$0.70 per share

Miscellaneous

Free Float
38,166,000
Market Cap
$28.03 million
Optionable
Optionable
Beta
1.40
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Ofer Haviv CPA (Age 58)
    CEO & President
    Comp: $390k
  • Dr. Nir Arbel (Age 44)
    Chief Product Officer
    Comp: $228k
  • Dr. Brian Ember (Age 48)
    Chief Executive Officer of AgPlenus Ltd
    Comp: $287k
  • Dr. Elran Hillel Haber M.B.A. (Age 44)
    Ph.D., Chief Executive Officer of Biomica Ltd
    Comp: $302k
  • Mr. Amit Noam Capt. res. (Age 42)
    Chief Executive Officer of Lavie Bio Ltd.
    Comp: $136k
  • Mr. Yaron Eldad (Age 59)
    Chief Financial Officer
  • Mr. Mark Kapel (Age 47)
    Chief Technology Officer
    Comp: $276k
  • Rachel Pomerantz Gerber
    Head of Investor Relations
  • Mr. Sassi Masliah (Age 45)
    Vice President of Corporate Development
    Comp: $245k
  • Ms. Liat Foigel Wejgman
    Vice President of Human Resources

EVGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Evogene stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EVGN shares.
View EVGN analyst ratings
or view top-rated stocks.

What is Evogene's stock price target for 2024?

3 Wall Street research analysts have issued 1 year price targets for Evogene's stock. Their EVGN share price targets range from $1.85 to $6.00. On average, they predict the company's stock price to reach $3.62 in the next twelve months. This suggests a possible upside of 431.9% from the stock's current price.
View analysts price targets for EVGN
or view top-rated stocks among Wall Street analysts.

How have EVGN shares performed in 2024?

Evogene's stock was trading at $0.84 on January 1st, 2024. Since then, EVGN stock has decreased by 19.0% and is now trading at $0.68.
View the best growth stocks for 2024 here
.

Are investors shorting Evogene?

Evogene saw a drop in short interest during the month of May. As of May 31st, there was short interest totaling 49,400 shares, a drop of 20.8% from the May 15th total of 62,400 shares. Based on an average daily trading volume, of 85,500 shares, the short-interest ratio is presently 0.6 days.
View Evogene's Short Interest
.

When is Evogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 15th 2024.
View our EVGN earnings forecast
.

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) announced its earnings results on Thursday, March, 7th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.01. The biotechnology company earned $0.58 million during the quarter, compared to the consensus estimate of $1.73 million. Evogene had a negative net margin of 233.66% and a negative trailing twelve-month return on equity of 70.96%. During the same quarter last year, the firm posted ($0.07) earnings per share.

What other stocks do shareholders of Evogene own?
Who are Evogene's major shareholders?

Evogene's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BNP Paribas Financial Markets (0.22%).

How do I buy shares of Evogene?

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EVGN) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners